trobalt
glaxo group limited - retigabine - epilepsy - antiepileptics, - trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
trobalt tablet 100 mg
glaxosmithkline pte ltd - retigabine - tablet, film coated - 100.0 mg
trobalt tablet 200 mg
glaxosmithkline pte ltd - retigabine - tablet, film coated - 200.0 mg
trobalt tablet 300 mg
glaxosmithkline pte ltd - retigabine - tablet, film coated - 300.0 mg
trobalt tablet 50 mg
glaxosmithkline pte ltd - retigabine - tablet, film coated - 50.0 mg
trobalt 50mg tablets
glaxosmithkline uk ltd - retigabine - tablet - 50mg
trobalt 400mg tablets
glaxosmithkline uk ltd - retigabine - tablet - 400mg
trobalt 300mg tablets
glaxosmithkline uk ltd - retigabine - tablet - 300mg
trobalt 200mg tablets
glaxosmithkline uk ltd - retigabine - tablet - 200mg
trobalt 100mg tablets
glaxosmithkline uk ltd - retigabine - tablet - 100mg